Stay up-to-date with all the local and international news from the HARTMANN GROUP.

HARTMANN publishes Quarterly Report 3/2022. Business developments affected by a tense economic and geopolitical situation

Company already complies with all requirements of the EU Medical Device Regulation (MDR)

HARTMANN GROUP and Rimasys Group have joined forces to support orthopedic and medical emergency professionals with the education and products they need to achieve the best possible outcomes for patients in the operating theater.

HARTMANN's business performance in the first nine months of 2022 is the result of significantly increased material, transportation and energy costs. Currency effects also had a negative impact. In addition, supply chains remained destabilized and there were risks with regard to energy supply.

Massive increases in costs for materials, transportation and energy significantly impacted the Company's business performance in the first half of 2022. With the outbreak of the Russian Ukrainian war, raw material prices continued to rise, which increasingly destabilized global supply chains and energy supplies.

Since the beginning of the COVID 19 pandemic at the latest, it has been known how important good hand hygiene is. The digital NosoEx® system from GWA Hygiene provides targeted support for nurses, doctors and hygienists. As part of its digital approach, HARTMANN will begin distributing the hygiene solution for healthcare facilities, thereby strengthening its Mission: Infection Prevention program.

The rising costs of materials, transportation, and energy, already on the rise since last year, significantly impacted HARTMANN's business performance in the first three months of 2022. The outbreak of the Russian-Ukrainian war exacerbated this development even further. By contrast, for the first time since its outbreak, the coronavirus pandemic no longer had a significant impact on business development. No positive effects materialized as a result of the extraordinary economic situation caused by the pandemic and the market gradually returned to normal, albeit at a reduced level.

Health care company HARTMANN is announcing price increases in most product categories and markets to compensate the significant higher costs for raw material, energy and freight that have been hitting the markets for several months.

The 2021 financial year was again dominated by the strong impact of the coronavirus and progress with the Transformation Program. The expected decline in key financial figures is mainly due to the pandemic. The pandemic-related extraordinary demand for disinfectants and personal protective equipment subsided as our customers meanwhile had large supplies on stock. There continued to be a reduced market with low bed occupancy rates in medical facilities and only a gradual increase in the number of surgeries and visits to doctors and pharmacies. Significantly higher material and transport costs also had an impact. By contrast, the strategic Transformation Program had a very positive impact on Group earnings.

The HARTMANN GROUP expects a moderate organic decline in sales for financial year 2022 with an adjusted EBITDA in the range of EUR 180 to 220 million, which corresponds to a decline of approximately EUR 35 million as compared to 2021.

As part of its transformation program, the HARTMANN GROUP will invest a total of approximately 40 million euros in the production site at Herbrechtingen between 2021 and 2023. 20 million will be used for a new production line and a further 20 million euros for the modernization of existing facilities and infrastructure.

The coronavirus pandemic continued to have a significant impact on HARTMANN's business development in the third quarter of 2021. Across all business segments, the Company generated revenue of EUR 1,704.9 million in the first nine months of the 2021 financial year. This equates to a moderate organic decline in revenue of -5.6% compared to the same period of the previous year. This means that the development of sales has been declining for three quarters in a row. In the third quarter of 2021 alone, profitability is at its lowest level in three years due to pandemic-related economic conditions in the market.

The impact of the coronavirus pandemic on the HARTMANN GROUP's business development did not significantly diminish in the first six months of financial year 2021. The positive effects resulting from the pandemic, which were clearly visible in 2020, declined considerably, in particular, the demand for disinfection products and personal protective equipment. At the same time, the pandemic’s negative effects have largely persisted. Also, rising raw material, freight and logistics costs had a negative impact on the development of the business segments.

The HARTMANN GROUP, a leading European provider of system solutions for medical applications and care, will become the official hygiene partner of the Allianz Arena for the new 2021/2022 season. Spectators at future sporting events in the Allianz Arena will be offered even greater safety thanks to a holistic hygiene concept.

The coronavirus pandemic remains the dominant issue in the current financial year for HARTMANN's European core sales markets. The growth in sales seen over the course of the extraordinary year 2020, however, did not continue. Sales increases in the Infection Management segment compensated for a declining development in all other segments.

The year 2020 was significantly affected by its transformation program and the Covid-19 pandemic. The improvement in key financial figures, with considerable organic sales growth and a strong increase in earnings, is mainly due to temporary effects of the pandemic. There is a high degree of forecast uncertainty for 2021 as the further development of the pandemic remains unclear. German/English version of press release in the link: Fiscal Year 2020

Michel Kuehn and Dr. Raymund Heinen set to retire and Stefan Grote appointed as Board Member for Incontinence Management.